, Federation, IDF Diabetes Atlas, 2015.
Diabetes Working, Mechanisms in endocrinology: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus, Eur. J. Endocrinol, vol.174, issue.4, pp.127-165, 2016. ,
Diabetes Working, Mechanisms of diabetes mellitus-induced bone fragility, Nat. Rev. Endocrinol, vol.13, issue.4, pp.208-219, 2017. ,
Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes, Diabetes, vol.65, issue.7, pp.1757-1766, 2016. ,
Diabetes, bone and glucose-lowering agents: clinical outcomes, Diabetologia, vol.60, issue.7, pp.1170-1179, 2017. ,
Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation, J. Cell. Physiol, vol.230, issue.8, pp.1944-1953, 2015. ,
Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women, JAMA, vol.305, issue.8, pp.783-789, 2011. ,
Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival, J. Cell. Physiol, vol.227, issue.4, pp.1326-1334, 2012. ,
The gut as a sensory organ, Nat. Rev. Gastroenterol. Hepatol, vol.10, issue.12, pp.729-740, 2013. ,
The incretin concept today, Diabetologia, vol.16, issue.2, pp.75-85, 1979. ,
The biology of incretin hormones, Cell Metab, vol.3, issue.3, pp.153-165, 2006. ,
Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man, Histochemistry, vol.56, issue.1, pp.37-44, 1978. ,
Evidence for preferential stimulation of gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates and their analogues, J. Endocrinol, vol.85, issue.2, pp.201-207, 1980. ,
K-cells and glucose-dependent insulinotropic polypeptide in health and disease, Vitam. Horm, vol.84, pp.111-150, 2010. ,
Dietary regulation of glucose-dependent insulinotropic peptide (GIP) gene expression in rat small intestine, Comp. Biochem. Physiol. Part C Pharmacol. Toxicol. Endocrinol, vol.110, issue.2, pp.207-214, 1995. ,
Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal, Am. J. Physiol, vol.266, issue.5, pp.887-91, 1994. ,
Receptors and effects of gut hormones in three osteoblastic cell lines, BMC Physiol, vol.11, p.12, 2011. ,
Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors, Endocrinology, vol.141, issue.3, pp.1228-1235, 2000. ,
Deficiency in glucose-dependent insulinotropic peptide receptor results in higher bone mass in male mice, Osteoporos. Int, vol.23, pp.407-415, 2012. ,
Effects of glucose-dependent insulinotropic peptide on osteoclast function, Am. J. Physiol. Endocrinol. Metab, vol.292, issue.2, pp.543-551, 2007. ,
Expression of glucagon-like peptide-1 receptor and glucosedependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells, Int. J. Mol. Med, vol.34, issue.2, pp.475-482, 2014. ,
Glucose-dependent insulinotropic polypeptide (GIP) directly affects collagen fibril diameter and collagen cross-linking in osteoblast cultures, Bone, vol.74, pp.29-36, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01392274
Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption, Bone, vol.91, pp.102-112, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01392269
Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion, Mol. Endocrinol, vol.20, issue.7, pp.1644-1651, 2006. ,
Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity, J. Biol. Chem, vol.288, issue.3, pp.1929-1938, 2013. ,
Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions, Diabetes, vol.63, issue.7, pp.2332-2343, 2014. ,
Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover, Bone, vol.37, issue.6, pp.759-769, 2005. ,
Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice, Bone, vol.53, issue.1, pp.221-230, 2013. ,
Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality, Bone, vol.56, issue.2, pp.337-342, 2013. ,
Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene, Diabetes, vol.47, issue.4, pp.646-652, 1998. ,
Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis, Am. J. Physiol. Endocrinol. Metab, vol.284, issue.5, pp.931-940, 2003. ,
, Peptides, 2017.
Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/-mice, Diabetes, vol.47, issue.7, pp.1046-1052, 1998. ,
Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength, Osteoporos. Int, vol.26, issue.1, pp.209-218, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01392271
Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis, Cell Metab, vol.25, issue.1, pp.152-165, 2017. ,
Therapeutic potential for GIP receptor agonists and antagonists, Best Pract. Res. Clin. Endocrinol. Metab, vol.23, issue.4, pp.499-512, 2009. ,
Chappard, Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties, Bone, vol.63, pp.61-68, 2014. ,
Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus, J. Cell. Physiol, vol.230, issue.12, pp.3009-3018, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01392285
Role of gastrointestinal hormones in postprandial reduction of bone resorption, J. Bone Miner. Res, vol.18, issue.12, pp.2180-2189, 2003. ,
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans, J. Clin. Endocrinol. Metab, vol.99, issue.11, pp.2325-2334, 2014. ,
A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk, J. Clin. Endocrinol. Metab, vol.99, issue.4, pp.729-762, 2014. ,
Pharmacological characterization of human incretin receptor missense variants, J. Pharmacol. Exp. Ther, vol.332, issue.1, pp.274-280, 2010. ,
Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes, vol.43, issue.4, pp.535-539, 1994. ,
, Biology of incretins: GLP-1 and GIP, vol.132, pp.2131-2157, 2007.
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors, Diabetologia, vol.48, issue.4, pp.612-615, 2005. ,
Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes, Life Sci, vol.92, issue.10, pp.533-540, 2013. ,
Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice, Bone, vol.81, pp.459-467, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01567148
Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor, J. Cell. Physiol, vol.225, issue.2, pp.585-592, 2010. ,
Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes, J. Endocrinol, vol.173, issue.3, pp.465-473, 2002. ,
Glucagon-like peptide-1 binding to rat hepatic membranes, J. Endocrinol, vol.146, issue.1, pp.183-189, 1995. ,
Modulation of glucagon receptor pharmacology by receptor activity-modifying protein-2 (RAMP2), J. Biol. Chem, vol.290, issue.38, pp.23009-23022, 2015. ,
Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor, J. Endocrinol, vol.219, issue.1, pp.59-68, 2013. ,
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption, Endocrinology, vol.149, issue.2, pp.574-579, 2008. ,
GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation, Endocrinology, vol.153, issue.3, pp.1538-1547, 2012. ,
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists, J. Endocrinol, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02869252
Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow, Am. J. Physiol. Endocrinol. Metab, vol.298, issue.3, pp.634-677, 2010. ,
Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress, Int. J. Mol. Med, vol.37, issue.4, pp.889-900, 2016. ,
Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation, J. Mol. Endocrinol, vol.56, issue.3, pp.189-199, 2016. ,
Liraglutide attenuates the osteoblastic differentiation of MC3T3E1 cells by modulating AMPK/mTOR signaling, Mol. Med. Rep, vol.14, issue.4, pp.3662-3668, 2016. ,
Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through beta-catenin, Stem Cell Rep, vol.6, issue.4, pp.579-591, 2016. ,
c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines, Purinergic Signal, vol.12, issue.4, pp.647-651, 2016. ,
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3 K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving beta-catenin, Exp. Cell Res, 2017. ,
Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states, Calcif. Tissue Int, vol.84, issue.6, pp.453-461, 2009. ,
Villanueva-Penacarrillo, Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states, Regul. Pept, vol.159, issue.1-3, pp.61-66, 2010. ,
Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats, J. Diabetes, vol.7, issue.4, pp.584-588, 2015. ,
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study, Diabetes Obes. Metab, vol.15, issue.3, pp.204-212, 2013. ,
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, Int. J. Clin. Pract, vol.65, issue.4, pp.397-407, 2011. ,
Effects of anti-diabetic drugs on bone metabolism, Expert Rev. Endocrinol. Metab, vol.10, issue.6, pp.663-675, 2015. ,
Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats, J. Bone Miner. Res, vol.28, issue.7, pp.1641-1652, 2013. ,
Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes, PLoS One, vol.10, issue.7, p.132744, 2015. ,
Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice, PLoS One, vol.8, issue.2, p.57375, 2013. ,
Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion, Bone, vol.69, pp.68-79, 2014. ,
Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials, J. Diabetes, vol.6, issue.3, pp.260-266, 2014. ,
Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials, Endocrine, vol.48, issue.1, pp.107-115, 2015. ,
Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis, Calcif. Tissue Int, vol.97, issue.2, pp.104-112, 2015. ,
Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs, Calcif. Tissue Int, vol.97, issue.5, pp.506-515, 2015. ,
Type 2 diabetes and osteoporosis: a guide to optimal management, J. Clin. Endocrinol. Metab, vol.102, issue.10, pp.3621-3634, 2017. ,
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties, Biochem. Pharmacol, vol.85, issue.11, pp.1655-1662, 2013. ,
A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice, Diabetologia, vol.56, issue.6, pp.1417-1424, 2013. ,
, A new glucagon and GLP-1 co-agonist eliminates obesity in rodents, vol.5, pp.749-757, 2009.
,
, Peptides, 2017.
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Sci. Transl. Med, vol.5, issue.209, pp.209-151, 2013. ,
, A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents, vol.21, pp.27-36, 2015.
The novel GLP-1-gastrin dual agonist, ZP3022, increases beta-cell mass and prevents diabetes in db/db mice, Diabetes Obes. Metab, vol.15, issue.1, pp.62-71, 2013. ,
A novel glucagon-like peptide-1 (GLP-1)/ glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice, J. Biol. Chem, vol.288, issue.49, pp.35581-35591, 2013. ,
An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice, Diabetologia, vol.60, issue.3, pp.541-552, 2017. ,
A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice, Diabetes, vol.64, issue.8, pp.2996-3009, 2015. ,
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, vol.58, issue.10, pp.2258-2266, 2009. ,
Bone loss accompanying voluntary weight loss in obese humans, J. Bone Miner. Res, vol.9, issue.4, pp.459-463, 1994. ,
Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study, Osteoporos. Int, vol.12, issue.9, pp.763-768, 2001. ,
The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes, Cell Metab, vol.26, issue.2, pp.343-352, 2017. ,
A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus, Bone, vol.87, pp.102-113, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01392261